Licensing · MENA · Announced 1 Jul 2026
Adalvo → Doctors Pharmaceutical
Licensing deal between Adalvo and Doctors Pharmaceutical (Saudi Arabia), covering Semaglutide, announced 1 Jul 2026. Value: Undisclosed.
Parties: ADALVO LTD → DOCTORS PHARMACEUTICAL (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia (MEA ambition)
- Therapeutic area
- Metabolic / Diabetes
- Assets
- Semaglutide; Adapalene + BPO; Nintedanib
- Announced
- 1 Jul 2026
Our analysis
Why this matters.
Adalvo — a Malta-headquartered B2B pharmaceutical company that partners with over 140 companies across more than 130 countries, specialising in complex generics, 505(b)(2)s, peptides and GLP-1s — has signed three partnership agreements with Doctors Pharma , a physician-founded Saudi manufacturer based in Jeddah.
The full analysis is free to read with a work email on this page.
Source: Doctors Pharma